Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: Are patients undertreated?
暂无分享,去创建一个
[1] Sophie Sun,et al. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort. , 2014, Lung cancer.
[2] R. Doebele,et al. Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. , 2013, Clinical lung cancer.
[3] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[4] F. Khuri,et al. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. , 2013, The oncologist.
[5] N. Leighl,et al. Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] S. Kudoh,et al. First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] Thomas J. Smith,et al. Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy. , 2012, Lung cancer.
[8] B. Milleron,et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial , 2011, The Lancet.
[9] W. Franklin,et al. Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] G. Scagliotti,et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.
[11] M. Stokes,et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. , 2009, Lung cancer.
[12] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Ardizzoni,et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.
[14] N. Hanna,et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Fidias,et al. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. , 2006, Lung cancer.
[16] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[17] Ruth Etzioni,et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Bogaerts,et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[21] J. Dancey,et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] B. Hillner,et al. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort , 1998, Cancer.
[23] P Chomy,et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[25] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[26] N. Jersey.,et al. SENATE OF THE UNITED STATES , 2003 .